SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:his-23844"
 

Sökning: onr:"swepub:oai:DiVA.org:his-23844" > Head-to-head compar...

  • González-King, HernánResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)

Head-to-head comparison of relevant cell sources of small extracellular vesicles for cardiac repair : Superiority of embryonic stem cells

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • John Wiley & Sons,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:his-23844
  • https://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-23844URI
  • https://doi.org/10.1002/jev2.12445DOI
  • https://gup.ub.gu.se/publication/338853URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • CC BY 4.0 DEED© 2024 AstraZeneca R&D and The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.Correspondence Address: H. González-King; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden; email: hernan.gonzalez-king@astrazeneca.com; K. Jennbacken; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden; email: Karin.jennbacken@astrazeneca.comFunding information: Högskolan i Skövde, Grant/Award Number: grant# 20200014The authors of this manuscript acknowledge AstraZeneca early CVRM Cardiovascular for their resource management, to John Liddle and Stefan Geschwindner from AstraZeneca postdoc committee for their advice, to AstraZeneca Animal Sciences & Technologies staff for their in vivo support, to Märta Jansson for performing the flow cytometric characterization of cardiac progenitor cells and to Elisa Lázaro and Olga Shatnyeva from the exosome team in AstraZeneca for input and facilitating a smooth introduction to AstraZeneca’s exosome research, to the National Genomics Infrastructure in Stockholm funded by Science for Life Laboratory, the Knut and Alice Wallenberg Foundation and the Swedish Research Council, and SNIC/Uppsala Multidisciplinary Center for Advanced Computational Science for assistance with massively parallel sequencing and access to the UPPMAX computational infrastructure. We also thank M. Soriano at the core facility of electron microscopy-Centro de Investigación Príncipe Felipe. This manuscript was edited at Life Science Editors. This work was supported by the University of Skövde under grants from the Swedish Knowledge foundation [grant # 20200014].
  • Small extracellular vesicles (sEV) derived from various cell sources have been demonstrated to enhance cardiac function in preclinical models of myocardial infarction (MI). The aim of this study was to compare different sources of sEV for cardiac repair and determine the most effective one, which nowadays remains limited. We comprehensively assessed the efficacy of sEV obtained from human primary bone marrow mesenchymal stromal cells (BM-MSC), human immortalized MSC (hTERT-MSC), human embryonic stem cells (ESC), ESC-derived cardiac progenitor cells (CPC), human ESC-derived cardiomyocytes (CM), and human primary ventricular cardiac fibroblasts (VCF), in in vitro models of cardiac repair. ESC-derived sEV (ESC-sEV) exhibited the best pro-angiogenic and anti-fibrotic effects in vitro. Then, we evaluated the functionality of the sEV with the most promising performances in vitro, in a murine model of MI-reperfusion injury (IRI) and analysed their RNA and protein compositions. In vivo, ESC-sEV provided the most favourable outcome after MI by reducing adverse cardiac remodelling through down-regulating fibrosis and increasing angiogenesis. Furthermore, transcriptomic, and proteomic characterizations of sEV derived from hTERT-MSC, ESC, and CPC revealed factors in ESC-sEV that potentially drove the observed functions. In conclusion, ESC-sEV holds great promise as a cell-free treatment for promoting cardiac repair following MI. 

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Rodrigues, Patricia G.Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Albery, TamsinResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Tangruksa, BenyapaGothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,Translational Bioinformatics,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research(Swepub:gu)xtangb (författare)
  • Gurrapu, RamyaAstraZeneca India Private Limited, Neville Tower 11th Floor, Ramanujan IT SEZ, Rajv Gandhi Salai (OMR), Taramani, Tamil Nadu, Chennai, India (författare)
  • Silva, Andreia M.Discovery Sciences, Oligo Assay Development, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden ; Anjarium Biosciences AG, Schlieren, Switzerland (författare)
  • Musa, GentianResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Kardasz, DominikaResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Liu, KaiDiscovery Sciences, Oligo Assay Development, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden ; Pharmaceutical Sciences, Advanced Drug Delivery, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Kull, BengtResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Åvall, KarinResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Rydén-Markinhuhta, KatarinaResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Incitti, TaniaResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Sharma, NitinAstraZeneca India Private Limited, Neville Tower 11th Floor, Ramanujan IT SEZ, Rajv Gandhi Salai (OMR), Taramani, Tamil Nadu, Chennai, India (författare)
  • Graneli, CeciliaResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Valadi, Hadi,1963Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research,Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden(Swepub:gu)xvalha (författare)
  • Petkevicius, KasparasResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Carracedo, MiguelResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Tejedor, SandraHögskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden,Translational Bioinformatics(Swepub:his)tejs (författare)
  • Ivanova, AlenaDiscovery Sciences, Oligo Assay Development, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Heydarkhan-Hagvall, SepidehHögskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Chief Medical Office, Global Patient Safety, AstraZeneca, Mölndal, Sweden,Translational Bioinformatics(Swepub:his)heys (författare)
  • Menasché, PhillipeDepartment of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, Université de Paris, PARCC, INSERM, Paris, France (författare)
  • Synnergren, JaneGothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningsmiljön Systembiologi,Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,Translational Bioinformatics,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xsynja (författare)
  • Dekker, NiekDiscovery Sciences, Oligo Assay Development, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Wang, Quing -DongResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Jennbacken, KarinResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden (författare)
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Mölndal, SwedenInstitutionen för biovetenskap (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Extracellular Vesicles: John Wiley & Sons13:52001-3078

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst. Hantera kakor

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy